Alterity Therapeutics, a development stage company, engages in the research and development of therapeutic drugs in Australia. The company offers PBT-2, a Phase IIa clinical trial product for the treatment of Alzheimer's disease. Its product is designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company's product is also applied for other therapies, including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinson's disease, and other neurodegenerative diseases. Originally founded as Prana Biotechnology Limited in 1997 and is based in Melbourne, Australia.

Alterity Therapeutics Limited

Alterity Therapeutics engages in the development of therapies to treat neurodegenerative disease. It includes research and development of treatments for Alzheimer's and Huntington's disease. The company was founded by Geoffrey Paul Kempler as Prana Biotechnology Ltd. on November 11, 1997 and is headquartered in Parkville, Australia.

Alterity Therapeutics Limited (ATHE) : Buy or Sell